Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.
2.

[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].

Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Okusaka T.

Nihon Shokakibyo Gakkai Zasshi. 2012 Aug;109(8):1346-54. Review. Japanese. No abstract available.

PMID:
22863957
3.

A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.

Park H, Han SH, Kang H, Park K.

Int J Cardiol. 2012 Sep 20;160(1):e10-1. doi: 10.1016/j.ijcard.2011.12.114. No abstract available.

PMID:
22289299
4.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM.

J Hepatol. 2012 Oct;57(4):821-9. doi: 10.1016/j.jhep.2012.06.014.

5.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168.

PMID:
23601249
6.

A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.

Hagihara A, Teranishi Y, Kawamura E, Fujii H, Iwai S, Morikawa H, Enomoto M, Tamori A, Kawada N.

Intern Med. 2013;52(14):1589-92. Review.

7.

[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].

Fabries P, Pauleau G, Brardjanian S, Artéaga C, Guisset M, Coton T.

Presse Med. 2013 Feb;42(2):235-7. doi: 10.1016/j.lpm.2012.02.005. French. No abstract available.

PMID:
22425476
8.

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.

Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, Gentiluomo M, Belli LS.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6. doi: 10.1097/MEG.0b013e328359e550. Review.

PMID:
23044808
9.

Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.

Noda S, Shioya M, Hira D, Fujiyama Y, Morita SY, Terada T.

Cancer Chemother Pharmacol. 2013 Jul;72(1):269-72. doi: 10.1007/s00280-013-2187-9.

PMID:
23673446
10.

Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.

Francini E, Mazzaroppi S, Fiaschi AI, Petrioli R, Laera L, Roviello G, Pira T, Pellicelli AM, Bianco V.

J Am Geriatr Soc. 2014 Nov;62(11):2204-5. doi: 10.1111/jgs.13091. No abstract available.

PMID:
25413190
11.

Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.

Jia N, Liou I, Halldorson J, Carithers R, Perkins J, Reyes J, Yeh M, Stohr E, Rao S, Lin EH.

Anticancer Res. 2013 Jun;33(6):2797-800.

PMID:
23749944
12.

Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.

Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S, Tonini G.

Expert Rev Anticancer Ther. 2012 Oct;12(10):1283-8. doi: 10.1586/era.12.102.

PMID:
23094801
13.

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.

Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010.

PMID:
23182599
14.

Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.

İlknur T, Akarsu S, Çarsanbali S, Lebe B, Fetil E.

J Drugs Dermatol. 2014 Aug;13(8):899-900. No abstract available.

PMID:
25116964
15.

Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.

Tajiri K, Nakajima T, Kawai K, Minemura M, Sugiyama T.

Intern Med. 2015;54(6):597-600. doi: 10.2169/internalmedicine.54.3675.

16.

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.

Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E.

Clin Transl Oncol. 2013 Feb;15(2):146-53. doi: 10.1007/s12094-012-0902-3.

PMID:
22875650
17.

Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma.

Cha J, Seong J, Lee IJ, Kim JW, Han KH.

Yonsei Med J. 2013 Sep;54(5):1178-85. doi: 10.3349/ymj.2013.54.5.1178.

18.

[Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].

Zhao P, Chen D, Chen W, Yin XY, Yang D, Liang LJ.

Zhonghua Wai Ke Za Zhi. 2012 Jun;50(6):514-7. Chinese.

PMID:
22943944
19.

Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.

Chou JW, Cheng KS, Huang CW.

Intern Med. 2016;55(6):623-7. doi: 10.2169/internalmedicine.55.5712. Review.

20.

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

Kermiche-Rahali S, Di Fiore A, Drieux F, Di Fiore F, François A, Scotté M.

World J Surg Oncol. 2013 Aug 2;11(1):171. doi: 10.1186/1477-7819-11-171.

Items per page

Supplemental Content

Support Center